Mast cells originate from pluripotent hematopoietic stem cells, which circulate as CD34+ precursors until they migrate into tissues where they mature to long living effector cells. Mast cells are present in all environmentally exposed tissues, e.g., skin, intestine and the lung, where they can be detected in epithelium and tissue, often in close proximity to blood and lymph vessels, nerves and hair follicles. Different types of mast cells have been described. In humans, mast cell subtypes are named according to their protease content. MC\textsuperscript{T} cells store tryptase in their granula in contrast to MC\textsuperscript{CT} cells which express both chymase and tryptase. MC\textsuperscript{T} are found in the skin, lymph nodes and submucosa of stomach and intestine. In contrast, MC\textsuperscript{CT} appear predominantly in the lung and the intestinal mucosa in close proximity to other immune cells such as T cells. Two types of mast cells can be distinguished in rodents: Mast cells which reside in mucosal tissue have been named mucosal mast cells (MMC), whereas serosal mast cells can be found in connective tissue (CTMC). These subtypes vary in their sensitivity of activation and mediator profile. Mast cells interact with their environment by a host of mediators: Some of them are stored in mast cell granula and some are produced de novo following activation. Mast cell mediators can be divided into the following classes; a) preformed substances, b) lipid mediators and c) cytokines and chemokines. Heparin, the neutral proteases chymase, tryptase and carboxipeptidase A as well as amines like...
histamine are stored in preformed form in the granula and can be released within minutes following mast cell activation. Lipid mediators are generated from arachidonic acid by cyclooxygenases (COX) and prostaglandin endoperoxide synthase-1 and -2 to prostaglandin 2 (PGD2) by 5-lipoxygenase to leukotriene A4 (LTA4). LTA4 can be further metabolized to LTB4, LTC4 or LTD4. Finally, mast cells are a source of a huge spectrum of cytokines and chemokines. Some cytokines can be stored in granules in preformed fashion. For example, tumor necrosis factor (TNF) can be immediately released from granules upon activation of mast cells and is also newly sensitized.11,12

Depending on the type and strength of stimulation, mast cells are able to release different mediator patterns within minutes. Mast cell activation and degranulation following IgE-mediated crosslinking of the membrane bound IgE high affinity receptor (FcrRI) is the best characterized pathway of mast cell activation.13,14 Crosslinking can be mediated by bi- or multivalent antigens, recognized by membrane-bound IgE molecules or unspecifically through super antigens. Following activation, granules fuse with the cell membrane and release their stored mediators within minutes. The metabolism of arachidonic acid and subsequent release of PGD2 and leukotrienes follows the degranulation, and finally, the de novo synthesis of cytokines and chemokines is induced.15-17 IgE-dependent mast cell activation without cross linking of FcrRI is still a controversially discussed mechanism of mast cell activation.18 During this process, single receptor-bound IgE molecules induce cytokine production even without crosslinking of FcrRI and regulate mast cell homeostasis. In addition to the FcrRI receptor, mast cells express Fcγ receptors. IgG mediated mast cell activation via these receptors plays an important role in murine models of autoimmune diseases such as arthritis and encephalitis.19,20 In mice, mainly IgG1 antibodies have been shown to contribute to Fcγ receptor-mediated activation and degranulation of mast cells.21 Mast cell can express a variety of Fcγ receptors, and FcγRIIB among these shows a negative regulatory effect on IgE mediated mast cell activation.22,23 Studies in FcγRIIB-deficient mice revealed increased anaphylactic reactions and higher susceptibility to allergic rhinitis;24-26 supporting the role of FcγRIIB as a negative regulator of mast cell activation.

In addition to immunoglobulins, mast cells can be activated further by exogenous and endogenous stimuli. Mast cells express a variety of receptors affiliated to innate but also adaptive immunity. Receptors of innate immunity are characterized by their ability to detect specific microbial patterns. Activation via these receptors leads to a fast immunological response, aiming at the quick clearance of the pathogen and induction of a supporting and appropriate adaptive immune response, if necessary. As mentioned before, mast cells reside in every tissue having contact to the environment, and they are one of the first cells which encounter pathogens. So far, the expression of Toll like receptors (TLR) -1,-2,-3,-4; -6, -7 and -9 as well as complement receptors and CD48 have been detected on the surface and within mast cells.20 Depending on the ligand, activation via TLR leads to distinct pattern of mediator release.27,28

The investigation of mast cell function in different immunological settings has greatly advanced with the availability of mast cell-deficient animals as a tool to analyze mast cell-dependent effects in vivo. Mast cell-deficient animals have a defective c-kit signalling either on the side of the receptor or on side of the ligand, stem cell factor (SCF).29,30 The SCF/c-kit signalling represents an important step in the development of mast cells. The WBB6F1-KitWsh/Wsh (W/W) and the C57BL/6-KitW/w (W/W) mouse represent the common used mouse strains to analyze mast cell specific effects. Both strains have mutations in the c-kit gene region, resulting in a defective expression of this receptor.31 The W/W is a combination of 2 mutations; KitW is a point mutation in an exon/intron border, leading to the loss of the receptor trans-membrane region,32 and KitWsh is also a point mutation, resulting in a defective signalling of the receptor.33 Consequently, W/W mice are devoid of mast cells. However, W/W mice show many phenotypic abnormalities resulting from additional effects of the mutation such as anaemia, infertility, and lack of interstitial cells of Cajal. Moreover, in these animals spontaneous dilatations of the stomach, papillomas of the forestomach, dermatitis and gastric ulcers have been observed. Because of these features, the C57BL/6-KitW/w mice have become a most popular choice as mast cell-deficient animals. The KitW/w mutation is a inversion in regulatory elements upstream of the c-kit element.34,35 Animals bearing this mutation are white and mast cell deficient, nevertheless, they are still fertile36 and not anaemic.37 For a closer analysis of mast cell function, it is possible to reconstitute mast cell deficient animals with in vitro generated mast cells.38-40 To investigate the effects of single mediators/receptors, the cells can be generated from transgenic or gene-deficient animals. Reconstitution can be performed by intradermal, intravenous or intraperitoneal application of the in vitro generated cells. Following a period of 4-8 weeks, most tissues are repopulated with mast cells.39,40 These models have helped to further unravel the role of mast cells and their mediators in innate as well as adaptive immune responses and different diseases, including allergic asthma. More recently, new approaches have been used to investigate mast cell models in vivo. Indeed, mast cell specific Cre recombinase-expressing mice have been generated by Cre expression under the control of mast cell protease 5 promoter.41 These approaches will allow to control mast cell specific gene-expression as well as target-
ed depletion of mast cells. However, mast cell protease 5 is expressed in CTMC but not in MMC, thus making this model unapplicable in allergic airway disease.

**MAST CELLS IN ADAPTIVE IMMUNITY**

The induction of an adequate adaptive immune response is essential for a long lasting protection against pathogens. However, disregulated adaptive immune responses are the cause of many diseases; e.g., autoimmunity and allergy. In the last few decades, increasing evidence suggested that mast cells can induce and modulate adaptive immune responses and thereby contribute to the development of different diseases. Dendritic cells (DC) are the most specialised antigen-presenting cells of the body and the most important cells for inducing adaptive immune responses. Following activation, DC mature and migrate to the draining lymph nodes, where they act as antigen presenting cells by activating antigen specific T cells. Depending on the cytokine milieu, Th0, Th1, Th2, Th9, Th17 as well as regulatory T cells (Tregs) can be induced. Importantly, in several models mast cells and mast cell-produced mediators directly modulate activation and migration of DC. Indeed, mast cells induce the migration of Langerhans cells from the skin to the draining lymph nodes following activation by IgE and allergen, but also following IgE-independent activation. In models of contact hypersensitivity, mast cells are necessary for effective sensitization, and especially, mast cell-produced TNF is responsible for enhanced migration of DC from the skin to the draining lymph nodes. Also in the lung, sensitized wild type (WT) animals show an enhanced migration of antigen-laden DC to the draining lymph node following local challenge.

The importance of mast cells for the induction of adaptive immune responses has further been corroborated by studies using IgE-independent mast cell activation. Application of a peptide in combination with a TLR7 ligand resulted in mast cell-dependent migration of antigen-presenting cells from the skin to regional lymph nodes and induction of a cytotoxic T cell response. Especially, cytokines IL1β and TNF produced by mast cells played a pivotal role in this setting.

Mast cell-produced mediators can also activate antigen presenting cells. Indeed, the mast cell produced mediators histamine, PDE1 and PGD2 modulate DCs to induce the development of Th0 responses. In addition, mast cells also activate T cells by cell contact-dependent and -independent mechanisms. Through the secretion of mediators, mast cells are able to attract T cells; e.g., to the regional lymph nodes, thereby inducing lymph node hyperplasia. Moreover, mast cells are also able to directly activate T cells. Especially, mast cell-produced TNF leads to the activation of T cells. In addition, in vitro studies have shown that mast cells can process antigens and are able to present them via MHC1 or MHCII complexes. Indeed, the expression of MHCII is confirmed for all mast cell subtypes and has been shown to lead to activation of CD8+ T cells in vitro. However, the expression of MHCII and upregulated costimulatory molecules remains controversial and seems to depend largely on the culture conditions. Interestingly, mast cells can release exosomes, bearing costimulatory molecules and antigen, which causes phenotypic and functional maturation of dendritic cells. However, many of the described phenomena have been observed only in vitro, and, therefore, it has to be shown that mast cells play a major role as antigen presenting cells in vivo.

**HUMAN ASTHMA AND MAST CELLS**

Asthma is a chronic inflammatory disease of the airways which shows heterogenous clinical phenotypes. Approximately 8% of the adults and 14% of children in the western world are affected by asthma, making it one of the most widespread worldwide chronic diseases. Asthma phenotypes are mainly based on clinical characteristics and inflammation patterns observed in the airways. In childhood, asthma is differentiated into transient infant wheezing, non-atopic wheezing and allergic wheezing, however, the disease may also develop during or after puberty. Irrespective of the phenotype, asthma is pathophysiologically characterized by three major hallmarks: airway inflammation, bronchial hyperreactivity and obstruction. Inflammation is featured by the influx of inflammatory cells; e.g., T cells, neutrophils and eosinophils. The inflammatory pattern of cell types depends on the asthma phenotype, duration and severity of disease, and treatment. In human airways, mast cells can be found adjacent to blood vessels in the lamina propria of airway mucosa. Interestingly, in patients with asthma mast cells also migrate into other structures like airway epithelium, the mucous glands and airway smooth muscle. This anatomical proximity to key structures involved in asthma and in vitro evidence for direct interaction between mast cells and airway smooth muscle cells suggest that mast cells play a significant role in the pathophysiology of this disease. Mast cells and smooth muscle cells interact in a crosstalk as mast cells can induce TGF-β1 expression in smooth muscle cells via release of β tryptase, resulting in differentiation of the muscle cells into a more contractile phenotype. Moreover, airway smooth muscle cells can enhance mast cell survival in a cell contact-dependent manner and can induce mast cell degranulation, representing a new antigen independent type of mast cell
Nevertheless, mast cells seem not to influence proliferation and survival of smooth muscle cells.73

In patients with allergic asthma, inhalation of an aero-allergen leads to crosslinking of membrane bound IgE via the allergen, inducing rapid release of mast cell mediators such as histamine, leukotrienes, proteases and prostaglandins, which can be detected in increased concentration in the broncho-alveolar lavage (BAL) of allergen challenged patients.74-76 These mediators induce vasodilatation, contraction of the smooth muscle and mucous secretion. Moreover, these mediators also lead to the late phase response which is characterized by infiltrating inflammatory cells, eosinophils, CD4+ T cells, neutrophils, mast cells and basophils which are associated with swelling of the bronchial wall and increased non-specific airway hyperresponsiveness (AHR). The important role of mast cells is underlined by studies on histamine and leukotriene receptor antagonists or anti-IgE antibodies, which completely ameliorate the development of the early phase and also partly the late phase response.77-79

Despite these results, the role and function of mast cells in the initial development of allergic asthma cannot be investigated in humans for ethical reasons, and therefore, animal studies are needed to assess molecular and cellular interactions responsible for the induction and exacerbation of the disease. Especially, rodent (mouse and rat) models have been used to analyze the pathomechanisms of allergic airway disease. These models can mimic many features of human asthma. However, due to profound differences in physiology between mice and men, not all the findings with murine models can uncritically be transferred to human situation. Yet, murine models helped to reveal many pathophysiologically important aspects regarding the role of mast cells in the development of allergic asthma.80,81

MURINE MODELS FOR ALLERGIC ASTHMA AND MAST CELLS

Using murine models, the role of mast cells in the induction of an allergic airway disease has been intensively investigated. Airway hyperresponsiveness and inflammation are comparable between wild type mice and mice lacking either mast cells, B cells, IgE or FcεRI, when animals are sensitized systemically by injection of allergen in combination with an adjuvant and subsequently challenged via the airways.82-85 Yet, some studies showed that mast cells are necessary for an enhanced influx of eosinophils into the lung,86,87 for the induction of an increased airway hyperresponsiveness88 or for the induction of subepithelial fibrosis.89

In many immunisation protocols, aluminum hydroxide (Alum) is used as an adjuvant, which acts via NALP3 inflammasome90 and induces a strong Th2 polarisation in the system.91 Furthermore, alum has direct effects on mast cells and macrophages.92 In contrast, however, studies using sensitization protocols without additional adjuvant showed that mast cells are necessary for the induction of allergic airway disease.93 The important function of FcεRI for development of AHR and inflammation was further identified.94,95 In addition, using mast cell-deficient animals and engraftment with bone marrow-derived mast cell (BMMCs), the function of mast cell-derived mediators was assessed.

MAST CELL MEDIATORS IN ALLERGIC ASTHMA

Tumor necrosis factor (TNF)

Indeed, mast cell-deficient mice which were reconstituted with BMMCs from TNF-deficient donors showed less inflammation and AHR compared to reconstituted animals which received BMMCs from wild type donors.96,97 These findings have been supported by a variety of murine and also human studies. The expression of TNF is upregulated in the airways of asthmatics in comparison to healthy subjects,98 and intratracheal application of TNF in healthy subjects induces AHR and inflammation.99,100 Murine models confirmed that TNF is important for the induction of mucus gene expression101 and necessary for the late phase response.102 Thus, TNF-deficient animals fail to develop an allergic airway disease, compared to WT animals.103

Histamine

Another important mast cell-produced mediator is histamine which acts on different cell types via four distinct receptors (HR).104 Depending on the expression level of the receptors and the cell type, histamine can have different effects with pro- but also anti-inflammatory patterns. In regard to DC activation, H1R and H3R induce pro-inflammatory responses with increased antigen presentation, cytokine production and Th priming activity, whereas activation of H2R induces IL-10 secretion and a regulatory DC phenotype.105 In T cells, depending on the receptor expression pattern histamine can induce the production of Th cytokines such as IFN-γ or Th-specific cytokines like IL-4 and IL-13.106 Recently, it has also been demonstrated that pro-inflammatory effects of mast cell-derived histamine might be mediated by suppressing CD4+ CD25+ regulatory T cells.107 In allergic airway disease, Bryce, et al.108 demonstrated an important role of histamine acting via H1 receptor. Indeed, H1-receptor-deficient animals were not able to allergic airway disease following sensitization and challenge. Especially, H1 receptor-deficient animals showed a defect in T cell migration into the lung. Furthermore, H4

Sebastian Reuter, et al.
receptor also seems to play an important role in the histamine-dependent induction of allergic airway disease. Consequently, novel H4 receptor antagonists have been developed and have shown to be effective in suppressing the development of allergic airway disease in murine models.

**Prostaglandins**

Mast cells are also capable to synthesize different lipid mediators. Interestingly, animals over-expressing prostaglandin D2 (PGD2) develop increased airway inflammation and Th2 cytokine production following sensitization and challenge in comparison to WT animals. Furthermore, inhalation of PGD2 just before airway challenge results in worsening of allergic airway disease, whereas blocking PGD2 synthesis decreases inflammation. The effects induced by PGD2 are dependent on the respective receptor. Two receptors have been described; PGD2 receptor 1 (DP1) which has pro inflammatory effects, while the function of PGD2 receptor 2 or chemo-attractant homologous receptor expressed on Th2 cells (DP2 or CRTH2) is more controversial. In allergic airway disease models, CRTH2 agonists increased airway inflammation whereas the receptor antagonists decreased inflammatory effects, whereas the function of PGD2 receptor 2 or chemo-attractant homologous receptor expressed on Th2 cells (DP2 or CRTH2) is more controversial. In allergic airway disease models, CRTH2 agonists increased airway inflammation whereas the receptor antagonists decreased it. In mice deficient in CRTH2, however, increased numbers of eosinophils and higher amounts of IL-5 were detected following allergen sensitization and challenge, compared to wild-type littermates. However, human Th2 cells which express CRTH2 show increased production of Th2 cytokines following exposure to PGD2 in the absence of costimulation. This suggests that blockade of the CRTH2 receptor might be an attractive approach for the treatment of allergic asthma, and indeed, CRTH2 antagonists are being tested in clinical trials.

**Leukotrienes**

Leukotrienes are also mast cells-produced lipid mediators, which affect the development of allergic airway disease. Arachidonic acid represents the source material for its synthesis. A multiprotein complex which includes 5-lipoxygenase (5-LO) initiates the transformation of free arachidonic acid to reactive leukotriene A4 that can be further metabolized to different leukotriene subtypes. LTC4 synthase represents the key enzyme for the induction of cys leukotrienes (leukotriene C4, D4 and E4), whereas LTB4 conversion is initiated by LTA4 hydrolase. Several studies identified LTB4 to be important for the recruitment of T cells and dendritic cells. Moreover, LTC4 and LTD4 acting via the CysLT1 receptor, seem to be important for fibrosis and vascular injury. Inhalation application of LTE4, but not LTD4, induces the influx of inflammatory cells into the lung. Taken together, prostaglandins as well as leukotrienes seem to play crucial roles in modulating and attracting immunocompetent cells. Thus, these mediators could be key players in mast cell-dependent modulation of adaptive immune responses.

**Thymic stromal lymphopoietin (TSLP)**

Thymic stromal lymphopoietin (TSLP) is a cytokine produced mainly by keratinocytes, epithelial and stromal cells. TSLP expression in the lung is upregulated in patients with asthma, and mice deficient for the receptor do not develop allergic airway disease. TSLP was also shown to induce DC activation, leading to a Th2 inducing phenotype in human as well as in mice. Therefore, TSLP is an important factor in modulating adaptive immune responses towards Th2. Interestingly, mast cells express the TSLP receptor, and exposure to TSLP leads to expression of Th2 cytokines. In addition, mast cells can produce high levels of TSLP, following IgE-mediated activation, and are vital for the induction of TSLP expression following allergen exposure.

**MAST CELL AS MODULATORS OF DC AND T CELL RESPONSES IN THE AIRWAYS**

Recent evidence suggests that mast cells not only play an important role in the induction of allergic airway disease in already sensitized hosts, but also are involved directly in the induction of specific T cell responses to aeroallergens. Following exposure to aeroallergens, the usual outcome is tolerance, because most allergens are immunologically inert proteins, and inflammation does not develop even following chronic exposure. Resident pulmonary DCs are usually in a state specialized to internalize foreign antigens, but not able to activate naïve T cells. Stimulation of DCs with additional factors like ligands for TLR eventually leads to their activation, migration to the regional lymphatic tissue and induction of a specific T cell response by antigen presentation and increased expression of co-stimulatory molecules. There is increasing in vitro evidence, that activation of mast cells can modulate the differentiation of DCs to a Th2 biased phenotype by histamine and prostaglandin secretion. Also, several studies in vivo suggest the involvement of mast cells in T cell priming following inhaled allergen exposure. In addition to the administration of a protein allergen, low doses of bacterial lipopolysaccharide (LPS) can induce sensitization to the allergen mediated by TLR-4 and production of TNF. Indeed, following intranasal challenge with allergen in conjunction with low-dose LPS, mast cell-deficient mice fail to develop sensitization to the allergen, demonstrating that IgE-independent activation of mast cells is involved in the initiation of a T
Other protein allergens, like house dust mite allergens (D. pteronyssinus, D. farinae) have the potential to directly induce rapid IgE-independent release and de novo synthesis of mast cell mediators. In vitro assays of D. farinae-stimulated mast cells show that their supernatants attract monocytes and T cells, support T cell proliferation and promote Th cell development. Inhaled exposure to house dust mite can induce Th2 sensitization and an influx of activated Th2 effector cells into the lung in vivo. In further support of the role of mast cells in this process, administration of sodium cromoglycate, a mast cell stabilizer, during repeated house dust mite allergen exposure not only suppresses the production of acute mast cell mediators but also attenuates airway inflammation following repeated D. farinae exposure.

In summary, mast cells play an important role in innate and adaptive immunity. This is mainly due to their ability to produce a variety of proinflammatory and immunomodulatory mediators. Upon their activation, they promote the migration of antigen-exposed antigen-presenting cells to the regional lymph nodes. Consequently, mast cells, at least under certain conditions, are able to strongly promote the development of specific T cell responses and are also able to shape them. In the context of allergic asthma, mast cells have been shown to initiate and promote airway inflammation and AHR in murine models and human disease, which also involves secretion of several mast cell-produced mediators (Fig. 1). Taken together, these findings clearly demonstrate that mast cells are not only mere effector cells during allergic reactions, but also have a complex role in the induction and regulation of adaptive immune responses. In regard to allergic sensitization, the activation of mast cells seems to be an important regulatory step for the development of specific T cell responses to the allergen. Therefore, modulation of mast cell activation could be a potential therapeutic strategy for the prevention and treatment of allergic disease.
Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci U S A 1986;83:4464-8.
4. Irani AM, Craig SS, DeBlois G, Elson CO, Schechter NM, Schwartz LB. Deficiency of the tryptase-positive, chymase-negative mast cell type in gastrointestinal mucosa of patients with defective T lymphocyte function. J Immunol 1987;138:4381-6.
5. Goldstein SM, Kaempfer CE, Proud D, Schwartz LB, Irani AM, Wintrobe BU. Detection and partial characterization of a human mast cell carboxypeptidase. J Immunol 1987;139:2724-9.
6. Enerbäck L, Pipkorn U, Granerus G. Intraepithelial migration of nasal mucosal mast cells in hay fever. Int Arch Allergy Immunol 1986;80:44-51.
7. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Filiponsky AM, Williams CM, Tsai M. Mast cells as “tunable” effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005;23:749-86.
8. Murakami M, Matsumoto R, Austen KF, Arm JP. Prostaglandin endoperoxide synthase-1 and -2 couple to different transmembrane stimuli to generate prostaglandin D in mouse bone marrow-derived mast cells. J Biol Chem 1994;269:22269-75.
9. Urade Y, Uijihara M, Horiguchi Y, Igarashi M, Nagata A, Ikai K, et al. Mast cells contain spleen-type prostaglandin D synthetase. J Biol Chem 1990;265:371-5.
10. Murphy RC, Gijon MA. Biosynthesis and metabolism of leukotrienes. Biochem J 2007;405:379-95.
11. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature 1990;346:274-6.
12. Young JD, Liu CC, Butler G, Cohn ZA, Galli SJ. Identification, purification, and characterization of a mast cell-associated cytoplasmic factor related to tumor necrosis factor. Proc Natl Acad Sci U S A 1987;84:9175-9.
13. Metzger H. The receptor with high affinity for IgE. Immunol Rev 1992;125:37-48.
14. Turner H, Kinet JP. Signalling through the high-affinity IgE receptor Fc epsilonRI. Nature 1999;402:B24-30.
15. Mayr SJ, Zuberi RI, Liu FT. Role of immunoglobulin E and mast cells in murine models of asthma. Braz J Med Biol Res 2003;36:821-7.
16. Schweitzer-Stenner R, Pecht I. Death of a dogma or enforcing the artificial: monomeric IgE binding may initiate mast cell response by inducing its receptor aggregation. J Immunol 2005;174:4464-1.
17. Kawakami T, Galli SJ. Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol 2002;2:773-86.
18. Kalesnikoff J, Huber M, Lam V, Damen JE, Zhang J, Siraganian RP, et al. Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity 2001;14:801-11.
19. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002;297:1869-92.
20. Robbie-Ryan M, Tanzola MB, Secor VH, Brown MA. Cutting edge: both activating and inhibitory Fc receptors expressed on mast cells regulate experimental allergic encephalomyelitis disease severity. J Immunol 2003;170:1630-4.
21. Vaz NM, Prouvost-Danon A. Behaviour of mouse mast cells during anaphylaxis in vitro. Prog Allergy 1969;13:111-73.
22. Daëron M, Malbec O, Latour S, Arock M, Fridman WH. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 1995;95:577-85.
23. Daëron M, Latour S, Malbec O, Espinosa E, Pina P, Pasmans S, et al. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and Fc-R-dependent cell activation. Immunology 1995;3:635-46.
24. Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV. Augmented humoral and anaphylactic responses in Fc gamma RI-deficient mice. Nature 1996;379:346-9.
25. Ujike A, Ishikawa Y, Ono M, Yuasa T, Yoshino T, Fukumoto M, et al. Modulation of immunoglobulin (IgE)-mediated systemic anaphylaxis by low-affinity Fc receptors for IgG. J Exp Med 1999;189:1573-9.
26. Metz M, Siebenhaar F, Maurer M. Mast cell functions in the innate skin immune system. Immunobiology 2008;213:251-60.
27. DeBlois G, Conlon P, Marshall JS. IL-6 production by rat peritoneal mast cells is not necessarily preceded by histamine release and can be induced by bacterial lipopolysaccharide. J Immunol 1994;152:5468-76.
28. Dvorak AM. Piecemeal degranulation of basophils and mast cells is effected by vesicular transport of stored secretory granule contents. Chem Immunol Allergy 2005;85:135-84.
29. Kitamura Y, Go S, Hatanaka K. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 1978;52:447-52.
30. Kitamura Y, Go S. Decreased production of mast cells in S1/S1d anemic mice. Blood 1979;53:492-7.
31. Geissler EN, Ryan MA, Housman DE. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 1988;55:185-92.
32. Galli SJ, Zseo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol 1994;55:1-96.
33. Nocka K, Tan JC, Chiu E, Chu TY, Ray P, Traktman P, et al. Molecular bases of dominant negative and loss of function mutations at the murine c-kit/white spotting locus: W37, Wv, W41 and W. EMBO J 1990;9:1805-13.
34. Duttlinger R, Manova K, Chu TY, Gysslers C, Zelenetz AD, Bachvarova RF, et al. W-sash affects positive and negative elements controlling c-kit expression: ectopic c-kit expression at sites of kit-ligand expression affects melanogenesis. Development 1993;118:705-17.
35. Nigrovic PA, Gray DH, Jones T, Hallgren J, Kuo FC, Chaletzky R, et al. Genetic inversion in mast cell-deficient (W/sh) mice interrupts corin and manifests as hematopoietic and cardiac aberrancy. Am J Pathol 2008;173:1693-701.
36. Lyon MF, Glenister P. A new allele sash (Wsh) at the W locus and a spontaneous recessive lethal in mice. Genet Res 1982;39:315-22.
37. Tono T, Tsujimura T, Koshimizu U, Kasugai T, Adachi S, Isozaki K, et al. The kit-Gene was not transcribed in cultured mast cells of mast cell-deficient Wsash/Wsh mice that have a normal number of erythrocytes and a normal c-kit coding region. Blood 1992;80:1448-53.
38. Tsur SH, Tsur S, Bui J, Stenberg B, Ward C, Dvorak AM. Mast cells derived from embryonic stem cells: a model system for studying the effects of genetic manipulations on mast cell development, phenotype, and function in vivo and in vitro. Int J Hematol 2002;75:345-9.
39. Grimbaldeston MA, Chen CC, Filiponsky AM, Tsai M, Tam SY, Galli SJ. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 2005;167:835-48.
Erle DJ, et al. Tissue-selective mast cell reconstitution and differential lung gene expression in mast cell-deficient Kit(W-sh)/Kit(W-sh) sash mice. Clin Exp Allergy 2005;35:82-8.

41. Scholten J, Hartmann K, Gerbaulet A, Krieg T, Müller W, Testa G, et al. Mast cell-specific Cre/loxP-mediated recombination in vivo. Transgenic Res 2008;17:307-15.

42. Lambrecht BN, De Veerman M, Coyle AJ, Gutierrez-Ramos JC, Thielemans K, Pauwels RA. Myeloid dendritic cells induce Th: responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest 2000;106:551-9.

43. Vermuelen KY, Carro-Muino I, Lambrecht BN, Pauwels RA. Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. J Exp Med 2001;193:51-60.

44. van Rijt LS, Vos N, Willart M, Kleinjan A, Coyle AJ, Hoogsteden HC, et al. Essential role of dendritic cell CD80/CD86 costimulation in the induction, but not reactivation, of Th: effector responses in a mouse model of asthma. J Allergy Clin Immunol 2004;114:166-73.

45. Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunology 2008;123:326-38.

46. Jawdat DM, Albert EJ, Rowden G, Haidl ID, Marshall JS. IgE-mediated mast cell activation induces Langerhans cell migration in vivo. J Immunol 2004;173:5275-82.

47. Jawdat DM, Rowden G, Marshall JS. Mast cells have a pivotal role in TNF-independent lymph node hypertrophy and the mobilization of Langerhans cells in response to bacterial peptidoglycan. J Immunol 2006;177:1755-62.

48. Heib V, Becker M, Warger T, Rechtsteiner G, Tertilt C, Klein M, et al. Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TL7R ligand in mice. Blood 2007;110:9463-5.

49. Bryce PJ, Miller ML, Miyajima I, Tsai M, Galli SJ, Oettgen HC. Immune sensitization in the skin is enhanced by antigen-independent effects of IgE. Immunity 2004;20:381-92.

50. Suto H, Nakae S, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cell-associated TNF promotes dendritic cell migration. J Immunol 2006;176:4102-12.

51. Reuter S, Dehzad N, Martin H, Heinz A, Castor T, Sudowe S, et al. Mast cells induce migration of dendritic cells in a murine model of acute allergic airway disease. Int Arch Allergy Immunol 2010;151:214-22.

52. McIlroy A, Caron G, Blanchard S, Frémaux I, Duluc D, Delneste Y, et al. Histamine and prostaglandin E up-regulate the production of Th: attracting chemokines (CCL17 and CCL22) and down-regulate IFN-gamma-induced CXCL10 production by immature human dendritic cells. Immunology 2006;117:507-16.

53. Theiner G, Gessner A, Lutz MB. The mast cell mediator PGD2 suppresses IL-12 release by dendritic cells leading to Th: polarized immune responses in vivo. Immunobiology 2006;211:463-72.

54. Wang HW, Tedla N, Lloyd AR, Wakefield D, McNeil PH. Mast cell activation and migration to lymph nodes during induction of an immune response in mice. J Clin Invest 1998;102:1617-26.

55. McLachlan JB, Hart JP, Pizzo SV, Shelburne CP, Staats HF, Gunn MD, et al. Mast cell-derived tumor necrosis factor induces hypotherpody of draining lymph nodes during infection. Nat Immunol 2003;4:1199-205.

56. Nakae S, Suto H, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cells enhance T cell activation: Importance of mast cell-derived TNF. Proc Natl Acad Sci U S A 2005;102:6467-72.

57. Nakae S, Suto H, Ikura M, Kakurai M, Sedgwick JD, Tsai M, et al. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol 2006;176:2238-48.

58. Stelekati E, Bahri R, D’Orlando O, Orinska Z, Mittrücker HW, Langenhaun R, et al. Mast cell-mediated antigen presentation regulates CD8+ T cell effector functions. Immunity 2009;31:665-76.

59. Malaviya R, Twesten NJ, Ross EA, Abraham SN, Pfeifer JD. Mast cells process bacterial Ags through a phagocytic route for class I MHC presentation to T cells. J Immunol 1996;156:1490-6.

60. Gauchat JF, Henchsz C, Mazzei G, Aubry JP, Brunner T, Blasey H, et al. Induction of human IgE: synthesis in B cells by mast cells and basophils. Nature 1993;365:340-3.

61. Ponte C, Arock M, David B. MHC class II-dependent activation of CD4+ T cell hybridomas by human mast cells through superantigen presentation. J Leukoc Biol 1999;66:105-12.

62. Grubbe J, Karau L, Welker P, Ziegler A, Henz BM. Induction of MHC class II antigen expression on human HMC-1 mast cells. J Dermatol Sci 1997;16:67-73.

63. Kambayashi T, Allenspach EJ, Chang JT, Zou T, Shoag JE, Reiner SL, et al. Inducible MHC class II expression by mast cells supports effector and regulatory T cell activation. J Immunol 2009;182:4686-95.

64. Skokos D, Botros HG, Demeure C, Morin J, Peronet R, Birkenmeier G, et al. Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. J Immunol 2003;170:3037-45.

65. Taussig LM, Wright AL, Holberg CJ, Halonen M, Morgan WJ, Martinez FD. Tucson Children’s Respiratory Study: 1980 to present. J Allergy Clin Immunol 2003;111:661-75.

66. De Marco R, Locatelli F, Cervieri I, Bugiani M, Marinoni A, Giammanco G; Italian Study on Asthma in Young Adults study group. Incidence and remission of asthma: a retrospective study on the natural history of asthma in Italy. J Allergy Clin Immunol 2002;110:228-35.

67. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, et al. Interleukin-4,-5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994;10:471-80.

68. Carroll NG, Mutavdzic S, James AL. Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma. Thorax 2002;57:677-82.

69. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002;346:1699-705.

70. Yang W, Kaur D, Okayama Y, Ito A, Wardlaw AJ, Brightling CE, et al. Human lung mast cells adhere to human airway smooth muscle, in part, via tumor suppressor in lung cancer-1. J Immunol 2006;176:1238-43.

71. Woodman L, Siddiqi S, Cruse G, Sutcliffe A, Saunders R, Kaur D, et al. Mast cells promote airway smooth muscle cell differentiation via autocrine up-regulation of TGF-beta 1. J Immunol 2008;181:5001-7.

72. Hollins F, Kaur D, Yang W, Cruse G, Saunders R, Sutcliffe A, et al. Human airway smooth muscle promotes human lung mast cell survival, proliferation, and constitutive activation: cooperative roles for CADM1, stem cell factor, and IL-6. J Immunol 2008;181:2772-80.
Mast Cells and Asthma

73. Kaur D, Hollins F, Saunders R, Woodman L, Sutcliffe A, Cruse G, et al. Airway smooth muscle proliferation and survival is not modulated by mast cells. Clin Exp Allergy 2010;40:279-88.

74. Murray JJ, Tonnel AB, Brash AR, Roberts LJ 2nd, Gosset P, Workman R, et al. Prostaglandin D: is released during acute allergic bronchopass in man. Trans Assoc Am Physicians 1985; 98:275-80.

75. Liu MC, Hubbard WC, Proud D, Stealey BA, Galli SJ, Kagey-Sobotka A, et al. Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. Am Rev Respir Dis 1991;144:51-8.

76. Casale TB, Wood D, Richerson HB, Zehr B, Zavala D, Hummelinglake GW. Direct evidence of a role for mast cells in the pathogenesis of antigen-induced bronchoconstriction. J Clin Invest 1987;80:1507-11.

77. Roquet A, Duhénn B, Kamlin M, Iere E, Anstrén G, Binks S, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997;155:1856-63.

78. Hamilton A, Faiferman I, Stober P, Watson RM, O’Byrne PM. Prolanlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J Allergy Clin Immunol 1998;102:177-83.

79. Fahy JV, Fleming HE, Wong HH, Liu JT, Su QJ, Reimann J, et al. The effect of an anti-IgE monoclonal antibody on the early and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-34.

80. Taube C, Dakhama A, Gelfand EW. Insights into the pathogenesis of asthma utilizing murine models. Int Arch Allergy Immunol 2004;135:173-86.

81. Boyce JA, Austen KF. No audible wheezing: nuggets and conundrums from mouse asthma models. J Exp Med 2005;201:1869-73.

82. Takeda K, Hamelmann E, Joetham A, Shultz LD, Larsen GL, Irvin CG, et al. Development of eosinophilic airway inflammation and airway hyperresponsiveness in mast cell-deficient mice. J Exp Med 1997;186:449-54.

83. Hamelmann E, Takeda K, Schwarz J, Vella AT, Irvin CG, Gelfand EW. Development of eosinophilic airway inflammation and airway hyperresponsiveness requires interleukin-5 but not immunoglobulin E or B lymphocytes. Am J Respir Cell Mol Biol 1999;21:480-9.

84. Mehlhop PD, van de Rijn M, Goldberg AB, Brewer JP, Kurup V, Martin TR, et al. Allergen-induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthma. Proc Natl Acad Sci U S A 1997;94:1344-9.

85. MacLean JA, Sauty A, Luster AD, Drazen JM, De Sanctis GT. Antigen-induced airway hyperresponsiveness, pulmonary eosinophilia, and chemokine expression in B cell-deficient mice. Am J Respir Cell Mol Biol 1999;20:379-87.

86. Ogawa K, Kaminuma O, Kikikawa H, Kameda R, Ikezawa K, Suko M, et al. Primary role of CD4+ T cells and supplemental role of mast cells in allergic pulmonary eosinophilia. Int Arch Allergy Immunol 1999;120 Suppl 1:15-8.

87. Kung TT, Stelts D, Zurcher JA, Jones H, Umland SP, Kreutner W, et al. Mast cells modulate allergic pulmonary eosinophilia in mice. Am J Respir Cell Mol Biol 1995;12:404-9.
allergic inflammation of the airways in mice. J Allergy Clin Immunol 2007;119:680-6.

104. Jutel M, Blaser K, Akdis CA. Histamine in allergic inflammation and immune modulation. Int Arch Allergy Immunol 2005;137:82-92.

105. Mazzoni A, Young HA, Spitzer JH, Visintin A, Segal DM. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J Clin Invest 2001;108:1865-73.

106. Jutel M, Watanabe T, Klunker S, Akdis M, Thorum OA, Malol-epszy J, et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 2001;413:420-5.

107. Forward NA, Furlong SJ, Yang Y, Lin TJ, Hoskin DW. Mast cells down-regulate CD4+CD25+ T regulatory cell suppressor function via histamine H1 receptor interaction. J Immunol 2009;183:3014-22.

108. Bryce PJ, Mathias CB, Harrison KL, Watanabe T, Geha RS, Oettgen HC. The H1 histamine receptor regulates allergic lung responses. J Clin Invest 2006;116:1624-32.

109. Dunford PJ, O'Donnell N, Riley JP, Williams KN, Karlsson L, Thurmond RL. The histamine H2 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T cells. J Immunol 2006;176:7062-70.

110. Cowden JM, Riley JP, Ma JY, Thurmond RL, Dunford PJ. Histamine H1 receptor antagonism diminishes existing airway inflammation and dysfunction by modulation of Th2 cytokines. Respir Res 2010;11:86.

111. Fujitani Y, Kanoaka Y, Artake K, Udodome N, Okazaki-Hatake K, Urade Y. Pronounced eosinophilic lung inflammation and dysfunction by differential expression of H1 and H2 receptors. Nature 2001;413:420-5.

112. Irvin CG, Tu YP, Sheller JR, Funk CD. 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. Am J Physiol 1997;222:L1053-8.

113. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568-75.

114. Koller M, Bron J, Rauf M, König W. Cilastatin (MK 0791) is a potent and specific inhibitor of the renal leukotriene D4-dipeptidase. Biochem Biophys Res Commun 1985;131:974-9.

115. Lam BK, Penrose JF, Freeman GJ, Austen KF. Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. J Biol Chem 1994;269:7663-7.

116. Mazzoni A, Young HA, Spitzer JH, Visintin A, Segal DM. Histamine in allergic inflammation and immune modulation. Int Arch Allergy Immunol 2005;137:82-92.

117. Forward NA, Furlong SJ, Yang Y, Lin TJ, Hoskin DW. Mast cells down-regulate CD4+CD25+ T regulatory cell suppressor function via histamine H1 receptor interaction. J Immunol 2009;183:3014-22.

118. Bryant PA, Hirose Y, Hirose K, Hirose T, Hirose H. The role of histamine in the development of airway hyperresponsiveness. J Allergy Clin Immunol 2007;120:808-14.

119. Henderson WR Jr, Lewis DB, Albert RK, Zhang Y, Lamm WJ, Chiang GK, et al. The importance of leukotrienes in allergic inflammation in a mouse model of asthma. J Exp Med 1996;184:1483-94.

120. Miyahara N, Takeda K, Miyahara S, Tabe C, Hase K, Aoya T, et al. Leukotriene B4 receptor-1 is essential for allergen-mediated recruitment of CD8+ T cells and airway hyperresponsiveness. J Immunol 2005;175:4979-84.

121. Taube C, Miyahara N, Ott V, Swanson B, Takeda K, Loader J, et al. The leukotriene B4 receptor (BLT1) is required for effector CD8+ T cell-mediated, mast-cell-dependent airway hyperresponsiveness. J Immunol 2006;176:3157-64.

122. Takahashi Y, Murata T, Matsuoka T, Hirata M, Tanaka H, Takahashi Y, Murata T, et al. Prostaglandin D2 as a mediator of allergic inflammation in guinea-pig lungs. J Immunol Res 2002;413:420-5.

123. Lam BK, Penrose JF, Freeman GJ, Austen KF. Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. J Biol Chem 1994;269:7663-7.

124. Orning L, Hammarström S. Inhibition of leukotriene C and leukotriene D biosynthesis. J Biol Chem 1980;255:8023-6.

125. Miyahara N, Takeda K, Miyahara S, Tabe C, Joetham A, Koya T, et al. Leukotriene B4 receptor-1 is essential for allergen-mediated recruitment of CD8+ T cells and airway hyperresponsiveness. J Immunol 2005;175:4979-84.

126. Miyahara N, Takeda K, Miyahara S, Tabe C, Joetham A, Koya T, et al. Leukotriene B4 receptor-1 is essential for allergen-mediated recruitment of CD8+ T cells and airway hyperresponsiveness. J Immunol 2005;175:4979-84.

127. Robbiani DF, Finch RA, Jäger D, Muller WA, Sartorelli AC, Randolph GJ. The leukotriene C4 transporter MRPI regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 2002;103:757-68.

128. Al-Shami A, Spolski R, Kelly J, Keane-Myers A, Leonard WJ, Oettgen HC. The H1 histamine receptor regulates allergic lung inflammation and dysfunction by modulation of Th2 cytokines. Am J Respir Crit Care Med 2001;164:1495-500.

129. Henderson WR Jr, Lewis DB, Albert RK, Zhang Y, Lamm WJ, Chiang GK, et al. The importance of leukotrienes in allergic inflammation in a mouse model of asthma. J Exp Med 1996;184:1483-94.

130. Orning L, Hammarström S. Inhibition of leukotriene C and leukotriene D biosynthesis. J Biol Chem 1980;255:8023-6.

131. Miyahara N, Takeda K, Miyahara S, Tabe C, Joetham A, Koya T, et al. Leukotriene B4 receptor-1 is essential for allergen-mediated recruitment of CD8+ T cells and airway hyperresponsiveness. J Immunol 2005;175:4979-84.

132. Miyahara N, Takeda K, Miyahara S, Tabe C, Joetham A, Koya T, et al. Leukotriene B4 receptor-1 is essential for allergen-mediated recruitment of CD8+ T cells and airway hyperresponsiveness. J Immunol 2005;175:4979-84.

133. Robbiani DF, Finch RA, Jäger D, Muller WA, Sartorelli AC, Randolph GJ. The leukotriene C4 transporter MRPI regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 2002;103:757-68.
Chartier S, et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med 2007;20:253-8.

136. Okayama Y, Okumura S, Sagara H, Yuki K, Sasaki T, Watanabe N, et al. FcepsilonRI-mediated thymic stromal lymphopoietin production by interleukin-4-primed human mast cells. Eur Respir J 2009;34:425-35.

137. Miyata M, Nakamura Y, Shimokawa N, Ohnuma Y, Katoh R, Matsuoka S, et al. Thymic stromal lymphopoietin is a critical mediator of IL-13-driven allergic inflammation. Eur J Immunol 2009;39:3078-83.

138. Hammad H, Lambrecht BN. Recent progress in the biology of airway dendritic cells and implications for understanding the regulation of asthmatic inflammation. J Allergy Clin Immunol 2006;118:331-6.

139. Gosset P, Pichavant M, Faveeuw C, Bureau F, Tonnel AB, Trottein F. Prostaglandin D2 affects the differentiation and functions of human dendritic cells: impact on the T cell response. Eur J Immunol 2005;35:1491-500.

140. Kitawaki T, Kadowaki N, Sugimoto N, Kambe N, Hori T, Miyachi Y, et al. IgE-activated mast cells in combination with pro-inflammatory factors induce Th2-promoting dendritic cells. Int Immunol 2006;18:1789-99.

141. Eisenbarth SC, Piggott DA, Huleatt JW, Visintin I, Herrick CA, Bottomly K. Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 2002;196:1645-51.

142. Nigo YI, Yamashita M, Hirahara K, Shinnakasu R, Inami M, Kimura M, et al. Regulation of allergic airway inflammation through Toll-like receptor 4-mediated modification of mast cell function. Proc Natl Acad Sci U S A 2006;103:2286-91.

143. Machado DC, Horton D, Harrop R, Peachell PT, Helm BA. Potential allergens stimulate the release of mediators of the allergic response from cells of mast cell lineage in the absence of sensitization with antigen-specific IgE. Eur J Immunol 1996;26:2972-80.

144. Yu CK, Chen CL. Activation of mast cells is essential for development of house dust mite Dermatophagoides farinae-induced allergic airway inflammation in mice. J Immunol 2003;171:3808-15.

145. Cates EC, Fattouh R, Wattie J, Inman MD, Goncharova S, Coyle AJ, et al. Intranasal exposure of mice to house dust mite elicits allergic airway inflammation via a GM-CSF-mediated mechanism. J Immunol 2004;173:6384-92.